Drugs / pegylated interferon a-2a
pegylated interferon a-2a
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial · 1 missed | ||||||
| Phase 4 | NCT00877760 | Aug 2009 → Jul 2013 | chronic hepatitis B virus infection | Foundation for Liver Research | Completed | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00851890 Background | Mar → Jul 2009 | chronic hepatitis C virus infection | AbbVie | Completed | Mixed |
| Phase 3 | NCT01854528 Comparator | Jun 2013 → Nov 2014 | chronic hepatitis C virus infection | AbbVie | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Interferon a-2a | “followed by 26 days of ABT-333 or placebo with pegylated interferon a-2a (pegIFN) and ribavirin (RBV) combination therapy.” NCT00851890 ↗ |
| Known as | pegIFN | “followed by 26 days of ABT-333 or placebo with pegylated interferon a-2a (pegIFN) and ribavirin (RBV) combination therapy.” NCT00851890 ↗ |
| Known as | PegINF | “Pegylated Interferon a-2a (PegINF)” NCT01854528 ↗ |
| Route | Subcutaneous | “Pegylated interferon was administered at 180 μg subcutaneously once a week” NCT00851890 ↗ |